Search Result

Results for "

Antiplatelet agents

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (1) Bacterial (1) Calcium Channel (1) Cytochrome P450 (3) Glycoprotein VI (2) Isotope-Labeled Compounds (1) P2Y Receptor (8) Phosphodiesterase (PDE) (1) Prostaglandin Receptor (4) Protease Activated Receptor (PAR) (5) Src (1) Syk (1) Thrombin (1)
By Research Areas:	Cancer (8) Cardiovascular Disease (24) Infection (1) Inflammation/Immunology (2)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N1861

3-O-Methylquercetin tetraacetate Quercetin 3-O-methyl ether peracetate	P2Y Receptor	Cardiovascular Disease Cancer
3-O-Methylquercetin tetraacetate is an antiplatelet agent. 3-O-Methylquercetin tetraacetate has potent antiplatelet effect on arachidonic acid, collagen-induced and PAF-induced platelet aggregation .

HY-146498

Antiplatelet agent 1	P2Y Receptor	Cardiovascular Disease Cancer
Antiplatelet agent 1 (compound 7q) is a Ticagrelor analoguehas, possessing antiplatelet activity. Antiplatelet agent 1 can be used for researching platelet aggregation .

HY-146499

Antiplatelet agent 2	P2Y Receptor	Cardiovascular Disease Cancer
Antiplatelet agent 2 (compound 7p) is a Ticagrelor analoguehas, possessing antiplatelet activity. Antiplatelet agent 2 can be used for researching platelet aggregation .

HY-111755

*Oral antiplatelet* agent 1**	P2Y Receptor	Cardiovascular Disease
Oral antiplatelet agent 1 is a potent P2Y₁₂ receptor antagonist. Oral antiplatelet agent 1 exhibits excellent antiplatelet aggregation potency with an IC₅₀ value of 2.94 μM as well as antithrombotic efficacy in a rat ferric chloride model. Oral antiplatelet agent 1 shows a superior safety profile than Clopidogrel (HY-15283) in a rat tail-bleeding model. Oral antiplatelet agent 1 can be used to research thromboembolic disorders .

HY-N1723

2-Deacetoxytaxinine B

2-Deacetoxytaxinine B is a potent antiplatelet agent .

2-Deacetoxytaxinine B
2-Deacetoxytaxinine B is a potent antiplatelet agent .

HY-N3048

Piperlotine D	Others	Cardiovascular Disease
Piperlotine D is an antiplatelet aggregation agent. Piperlotine D can be extracted from Piper lolot with antiplatelet aggregation activity. Piperlotine D inhibits arachidonic acid-induced platelet aggregation with an IC₅₀ of 43.4 μg/mL .

HY-N3729

(-)-Denudatin B Denudatin B	Calcium Channel	Cardiovascular Disease
(-)-Denudatin B is an antiplatelet agent. (-)-Denudatin B relaxed vascular smooth muscle by inhibiting the Ca2+ influx through voltage-gated and receptor-operated Ca2+ channels . And (-)-Denudatin B has nonspecific antiplatelet action

HY-U00039

Desethyl KBT-3022

Thrombin Cardiovascular Disease

Desethyl KBT-3022 is the main active metabolite of the new antiplatelet agent, KBT-3022.

Desethyl KBT-3022	Thrombin	Cardiovascular Disease
Desethyl KBT-3022 is the main active metabolite of the new antiplatelet agent, KBT-3022.

HY-B0428

Ozagrel 1 Publications Verification OKY-046	Prostaglandin Receptor	Cardiovascular Disease
Ozagrel (OKY-046)is an anti-asthmatic agent and a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel is an antiplatelet agent, which selectively inhibits human platelet aggregation with an IC₅₀ of 53.12 μM .

HY-B0312

Dipyridamole 2 Publications Verification	Phosphodiesterase (PDE) Apoptosis	Cardiovascular Disease Cancer
Dipyridamole is an orally active phosphodiesterase (PDE) inhibitor. Dipyridamole also is an **antiplatelet agent** used in secondary prophylaxis against stroke. Dipyridamole can induce cancer cell-specific apoptosis .

HY-B0428A

Ozagrel sodium 1 Publications Verification OKY-046 sodium	Prostaglandin Receptor	Cardiovascular Disease
Ozagrel sodium (OKY-046 sodium) is a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel sodium is an antiplatelet agent, which selectively inhibits human platelet aggregation with an IC₅₀ of 53.12 μM .

HY-B0428B

Ozagrel hydrochloride 1 Publications Verification OKY-046 hydrochloride
Ozagrel hydrochloride (OKY-046 hydrochloride) is a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel hydrochloride is an antiplatelet agent, which selectively inhibits human platelet aggregationwith an IC₅₀ of 53.12 μM .

HY-A0221

Ridogrel R 68070	Prostaglandin Receptor	Inflammation/Immunology
Ridogrel (R 68070) is an orally active combined thromboxane A2 synthetase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor blocker. Ridogrel is potent antiplatelet agent. Anti-inflammatory activities .

HY-118284

Vicagrel 1 Publications Verification	P2Y Receptor	Cardiovascular Disease
Vicagrel is a potent, safe and orally active antiplatelet agent, which works by irreversibly inhibiting P2Y12 receptor. Vicagrel can be used for the research of blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease .

HY-106080A

Furegrelate sodium U-63557A	Others	Cardiovascular Disease
Furegrelate Sodium (U-63557A) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate Sodium inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC₅₀ of 15 nM. Furegrelate Sodium is being developed as an antiplatelet agent .

HY-107867

(±)-Clopidogrel bisulfate	Others	Cardiovascular Disease
Clopidogrel sulfate is an antiplatelet agent. Specifically, Clopidogrel sulfate inhibits the binding of ADP to its receptors on the membranes of platelet cells, and blocks ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. Clopidogrel sulfate can be used for research of heart disease and stroke .

HY-18200

Atopaxar E5555; ER-172594-00	Protease Activated Receptor (PAR)	Cardiovascular Disease
Atopaxar (E5555) is a potent, orally active, selective and reversible thrombin receptor protease-activated receptor-1 (PAR-1) antagonist. Atopaxar, an antiplatelet agent, interferes with platelet signaling. Atopaxar can be used for the research of atherothrombotic disease .

HY-106080

Furegrelate U-63557A free acid	Others	Cardiovascular Disease
Furegrelate (U-63557A free acid) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC₅₀ of 15 nM. Furegrelate is being developed as an antiplatelet agent .

HY-18200B

Atopaxar hydrobromide E5555 hydrobromide; ER 172594-06	Protease Activated Receptor (PAR)	Cardiovascular Disease
Atopaxar (E5555) hydrobromide is a potent, orally active, selective and reversible thrombin receptor protease-activated receptor-1 (PAR-1) antagonist. Atopaxar hydrobromide, an antiplatelet agent, interferes with platelet signaling. Atopaxar hydrobromide can be used for the research of atherothrombotic disease .

HY-N6005

Methyl caffeate	Bacterial	Infection Cancer
Methyl caffeate, an antimicrobial agent, shows moderate antimicrobial and prominent antimycobacterial activities. Methyl caffeate also exhibits α-glucosidase inhibition activity, oxidative stress inhibiting activity, anti-platelet activity, antiproliferative activity in cervix adenocarcinoma and anticancer activity in lung and leukmia cell lines .

HY-10119

Vorapaxar 5+ Cited Publications SCH 530348	Protease Activated Receptor (PAR)	Cardiovascular Disease
Vorapaxar (SCH 530348), an antiplatelet agent, is a selective, orally active, and competitive thrombin receptor protease-activated receptor (PAR-1) antagonist (K_i=8.1 nM). Vorapaxar (SCH 530348) inhibits thrombin receptor-activating peptide (TRAP)-induced platelet aggregation in a dose-dependent manner .

HY-10119A

Vorapaxar sulfate 5+ Cited Publications SCH 530348 sulfate	Protease Activated Receptor (PAR)	Cardiovascular Disease
Vorapaxar sulfate (SCH 530348 sulfate), an antiplatelet agent, is a selective, orally active, and competitive thrombin receptor protease-activated receptor (PAR-1) antagonist (K_i=8.1 nM). Vorapaxar sulfate inhibits thrombin receptor-activating peptide (TRAP)-induced platelet aggregation in a dose-dependent manner .

HY-17459

Clopidogrel hydrogen sulfate Maximum Cited Publications 17 Publications Verification (S)-(+)-Clopidogrel bisulfate; (S)-(+)-Clopidogrel hydrogen sulfate	Cytochrome P450 P2Y Receptor	Cardiovascular Disease Cancer
Clopidogrel hydrogen sulfate is an *antiplatelet* agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC₅₀s of 18.2 nM and 524 nM, respectively . Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation ．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor .

HY-10119S

Vorapaxar-d5 SCH 530348-d₅	Protease Activated Receptor (PAR) Isotope-Labeled Compounds	Cardiovascular Disease
Vorapaxar-d₅ is deuterated labeled Vorapaxar (HY-10119). Vorapaxar (SCH 530348), an antiplatelet agent, is a selective, orally active, and competitive thrombin receptor protease-activated receptor (PAR-1) antagonist (K_i=8.1 nM). Vorapaxar (SCH 530348) inhibits thrombin receptor-activating peptide (TRAP)-induced platelet aggregation in a dose-dependent manner .

HY-115911

GPVI antagonist 2	Glycoprotein VI	Cardiovascular Disease
GPVI antagonist 2 (Compound 1) is a potential antagonist of Glycoprotein VI (GPVI). IC₅₀ values of GPVI antagonist 2 are, respectively, 0.35 μM for collagen, 0.80 μM for CRP, 195.2 μM for convulxin and 81.38 μM for thrombin. Glycoprotein VI (GPVI) is a platelet major collagen receptor and a target for potent and safe antithrombotic research. GPVI antagonist 2 is a promising antiplatelet agent .

HY-115912

GPVI antagonist 3	Glycoprotein VI	Cardiovascular Disease
GPVI antagonist 3 (Compound 2) is a potential antagonist of Glycoprotein VI (GPVI). IC₅₀ values of GPVI antagonist 3 are, respectively, 1.01 μM for collagen, 1.92 μM for CRP, 7.24 μM for convulxin and 51.74 μM for thrombin. Glycoprotein VI (GPVI) is a platelet major collagen receptor and a target for potent and safe antithrombotic research. GPVI antagonist 3 is a promising antiplatelet agent .

HY-17459S

Clopidogrel-d3 hydrogen sulfate (S)-(+)-Clopidogrel bisulfate-d₃; (S)-(+)-Clopidogrel-d₃ hydrogen sulfate	P2Y Receptor Cytochrome P450
Clopidogrel-d₃ (hydrogen sulfate) is the deuterium labeled Clopidogrel hydrogen sulfate[1]. Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC50s of 18.2 nM and 524 nM, respectively. Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor[2][3][4][5][6].

HY-17459R

Clopidogrel hydrogen sulfate (Standard) (S)-(+)-Clopidogrel bisulfate (Standard); (S)-(+)-Clopidogrel hydrogen sulfate (Standard)	Cytochrome P450 P2Y Receptor	Cardiovascular Disease Cancer
Clopidogrel (hydrogen sulfate) (Standard) is the analytical standard of Clopidogrel (hydrogen sulfate). This product is intended for research and analytical applications. Clopidogrel hydrogen sulfate is an *antiplatelet* agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC₅₀s of 18.2 nM and 524 nM, respectively . Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation ．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor .

HY-78263

MNS NSC 170724; 5-(2-Nitrovinyl)benzodioxole	Src Syk	Cancer
MNS (NSC 170724), the beta-nitrostyrene derivative, is a potent tyrosine kinase inhibitor and a broad-spectrum antiplatelet agent. MNS completely inhibits U46619, ADP-, arachidonic acid-, collagen-, and thrombin-induced platelet aggregation with IC₅₀ values of 2.1, 4.1, 5.8, 7.0, and 12.7 μM, respectively. MNS inhibits Src, Syk, and FAK with IC₅₀ of 27.3, 2.8, and 97.6 μM, respectively .

HY-160615

TP receptor antagonist-1	Prostaglandin Receptor	Cardiovascular Disease Inflammation/Immunology
TP receptor antagonist-1 (compound 7m) is a thromboxane A₂ receptor (TP receptor) antagonist, with IC₅₀ values of 9.46 μM for TPa and 8.49 μM for TPb, respectively. TP receptor antagonist-1 can be used for the research of cardiovascular disease .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N3729

(-)-Denudatin B Denudatin B	Cardiovascular Disease Classification of Application Fields Piper betle L. Source classification Lignans Piperaceae Phenylpropanoids Plants Disease Research Fields	Calcium Channel
(-)-Denudatin B is an antiplatelet agent. (-)-Denudatin B relaxed vascular smooth muscle by inhibiting the Ca2+ influx through voltage-gated and receptor-operated Ca2+ channels . And (-)-Denudatin B has nonspecific antiplatelet action

HY-N6005

Methyl caffeate	Infection Classification of Application Fields Simple Phenylpropanols Source classification Phenols Polyphenols Solanum torvum Swartz Phenylpropanoids Plants Solanaceae Disease Research Fields	Bacterial
Methyl caffeate, an antimicrobial agent, shows moderate antimicrobial and prominent antimycobacterial activities. Methyl caffeate also exhibits α-glucosidase inhibition activity, oxidative stress inhibiting activity, anti-platelet activity, antiproliferative activity in cervix adenocarcinoma and anticancer activity in lung and leukmia cell lines .

HY-N1861

3-O-Methylquercetin tetraacetate Quercetin 3-O-methyl ether peracetate	Rhamnus nakaharai (Hayata) Hayata Structural Classification Flavonoids Flavones Source classification Plants Rhamnaceae	P2Y Receptor
3-O-Methylquercetin tetraacetate is an antiplatelet agent. 3-O-Methylquercetin tetraacetate has potent antiplatelet effect on arachidonic acid, collagen-induced and PAF-induced platelet aggregation .

HY-N3048

Piperlotine D	Structural Classification Alkaloids Pyrrole Alkaloids Piper sarmentosum Roxb. Source classification Piperaceae Plants	Others
Piperlotine D is an antiplatelet aggregation agent. Piperlotine D can be extracted from Piper lolot with antiplatelet aggregation activity. Piperlotine D inhibits arachidonic acid-induced platelet aggregation with an IC₅₀ of 43.4 μg/mL .

Cat. No.	Product Name	Chemical Structure

HY-10119S

Vorapaxar-d5
Vorapaxar-d₅ is deuterated labeled Vorapaxar (HY-10119). Vorapaxar (SCH 530348), an antiplatelet agent, is a selective, orally active, and competitive thrombin receptor protease-activated receptor (PAR-1) antagonist (K_i=8.1 nM). Vorapaxar (SCH 530348) inhibits thrombin receptor-activating peptide (TRAP)-induced platelet aggregation in a dose-dependent manner .

HY-17459S

Clopidogrel-d3 hydrogen sulfate
Clopidogrel-d₃ (hydrogen sulfate) is the deuterium labeled Clopidogrel hydrogen sulfate[1]. Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC50s of 18.2 nM and 524 nM, respectively. Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor[2][3][4][5][6].

Clopidogrel-d3 hydrogen sulfate

Clopidogrel-d₃ (hydrogen sulfate) is the deuterium labeled Clopidogrel hydrogen sulfate[1]. Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC50s of 18.2 nM and 524 nM, respectively. Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor[2][3][4][5][6].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks